5 results match your criteria: "Baoji Maternal and Child Health Hospital No. 2[Affiliation]"
Am J Transl Res
October 2024
Department of Gynaecology, Xianyang Maternal and Child Health Hospital Century Avenue, Qindu District, Xianyang 712000, Shaanxi, China.
Am J Transl Res
September 2024
Department of Obstetrical II, Baoji Maternal and Child Health Hospital No. 2 East Section of Xinjian Road, Weibin District, Baoji 721000, Shaanxi, China.
Am J Transl Res
April 2024
Department of Obstetrics, Ankang Central Hospital No. 85 Jinzhou South Road, Hanbin District, Ankang 725000, Shaanxi, China.
Am J Transl Res
July 2023
Department of Anesthesia and Operating Room, Baoji Maternal and Child Health Hospital No. 2, East Section of Xinjian Road, Weibin District, Baoji 721000, Shaanxi, China.
Objective: To compare the safety profiles between propofol and sevoflurane in pediatric anesthesia and to investigate risk factors for postoperative adverse reactions.
Methods: The data of 194 children who received surgical treatment in Peking Union Medical College Hospital between January 2019 and May 2022 were analyzed retrospectively. According to the different anesthetic drugs the children received, they were divided into a control group (conventional anesthesia with sevoflurane, n=94) and an observation group (anesthesia with both propofol and sevoflurane, n=100).
Am J Transl Res
November 2022
Department of Obstetrics, Baoji Maternal and Child Health Hospital No. 2, East Section of Xinjian Road, Weibin District, Baoji 721000, Shaanxi, China.
Objective: To explore the efficacy of Atosiban combined with Ritodrine treatment on spontaneous threatened preterm birth and its effect on platelet-activating factor (PAF) and fetal fibronectin levels.
Methods: Medical records from 120 patients with threatened preterm birth admitted to Baoji Maternal and Child Health Hospital from October 2020 to December 2021 were collected for this retrospective analysis. A total of 56 patients treated with Ritodrine alone were taken as the control group (CG), and the other 64 patients given combined treatment of Atosiban and Ritodrine were seen as the observation group (OG).